|

Anti-CFH Monoclonal Antibody GT103 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: GT 103, GT-103, GT103

Pipeline

Phase 2: 1

Top Sponsors

  • Roswell Park Cancer Institute1

Indications

  • Advanced Lung Non-Small Cell Carcinoma1
  • Stage III Lung Cancer AJCC v81
  • Stage IV Lung Cancer AJCC v81
  • Metastatic Lung Non-Small Cell Carcinoma1
  • Lung Cancer1

Buffalo, New York1 trial

GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer

Roswell Park Cancer Institute

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.